Likuiditas cepet: Bionano Genomics (BNGO)

The market value dynamics of Bionano Genomics, Inc. (BNGO) reflect a current figure of 1.96. The issuer's operations support the ESG agenda, as its instruments reduce energy consumption and reagent usage during research. The business relies on third-party chip supplies while maintaining full control over its proprietary software, yet it faces a capital shortage and slow market adoption of its systems.

Quick liquidity measures a business's ability to instantaneously settle short-term obligations using cash and accounts receivable, completely excluding slow-moving inventories. By analyzing the current quick ratio, an investor assesses the financial autonomy of Bionano Genomics, Inc. (BNGO) amidst costly R&D developments. For this high-tech manufacturer of genome mapping systems, this metric confirms resilience in the face of competition. A stable level of this metric guarantees the company's survival without the need for emergency capital raises.